Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2012

View Archived Issues

Scientists at Roche disclose new HDL cholesterol-raising agents

Reata Pharmaceuticals presents new inhibitors of NO production

Nerviano Medical Sciences prepares new protein kinase inhibitors

French scientists patent novel agents for AIDS

EVP-0015962 reduces total Abeta load

Swiss researchers patent novel anti-SOD1 antibodies

ST-101 triggers acetylcholine release via the Ca(V)3.1 channel

Ampio's anticancer candidate advances to preclinical development

Verastem provides update on pipeline projects

FDA accepts NDA for single-entity hydrocodone product

ASKP-1240 well tolerated in de novo kidney transplant recipients

St. Jude to study replacement therapy compounds from Retrophin

Phase I trial of bavituximab in rectal cancer commences

Encouraging results reported from phase I trial of ALN-TTR02

NuPathe resubmits migraine patch NDA

Novavax to provide VLP vaccine technology for public-private malaria partnership in India

GSK to acquire Human Genome Sciences

Anthera provides final data from PEARL-SC study

FDA approves drug to reduce risk of HIV infection

Biotest begins clinical study of BT-062 as part of combination therapy

Janssen R&D Ireland presents new antiviral agents

Clovis Oncology and Array BioPharma enter collaboration

Repros receives FDA guidance regarding phase II study in endometriosis

Lee's Pharmaceuticals licenses thymosin beta4 candidates in China and Taiwan

EW-7197 as a new therapeutic option for breast cancer metastasis

EMA accepts laquinimod MAA for relapsing-remitting multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...